Amyopathic dermatomyositis associated with immune checkpoint inhibitor therapy in lung adenocarcinoma: a case report
We believe this case represents a valuable clinical reference for the future management of irAEs caused by pembrolizumab and emphasizes the necessity of early screening for anti-melanoma differentiation associated protein 5 (MDA5) antibodies in patients with CIP presenting as RP-ILD.
Authors
- Takehiro Uemura
- Zhang Zhang (ORCID: https://orcid.org/0000-0002-4822-4471)
- Pengyi Guo
Institutions
- Nagoya City University (JP)
- Ningbo No. 2 Hospital (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/tcr-2024-2364
- Citations
- 1
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 1.35